Review proposal - May 2011
Review of TA142; Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia
In March 2009 we informed stakeholders of the decision to defer the consideration of a review of Technology Appraisal no. 142; Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia until February 2011.
The Institute has carried out a search for information relevant to this appraisal, and believes that it is appropriate for the guidance to be updated. A review of the guidance will therefore be planned into the NICE’s work programme. The appraisal will be scheduled to coordinate with the availability of results from the EVALUATE study. Three new erythropoietin-analogue products (including two 'biosimilar' products) will be included in the appraisal. This is subject to formal referral from the Department of Health.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 18 May 2011